Health phenome of Parkinson’s patients reveals prominent mood-sleep cluster
暂无分享,去创建一个
V. Khurana | I. Tuncali | Jordan Paulson | E. Abatzis | P. Kamenskaya | Gary P. H. Ho | Trond Riise | Abby Olsen | Joseph Locascio | Nada Laroussi | Yuliya Kuras | Tom Yi | Aleks Videnovic | Michael Hayes | Todd Herrington | Bradley Hyman | Dennis Selkoe | John Growdon | Stephen Gomperts | Michael Schwarzschild | Albert Hung | Anne Wills | Clemens Scherzer
[1] Jae-Myung Kim,et al. Restless legs syndrome affects sleep in de novo Parkinson’s disease patients , 2023, Medicine.
[2] C. Vitale,et al. Prevalence and clinical aspects of obstructive sleep apnea in Parkinson disease: A meta‐analysis , 2023, European journal of neurology.
[3] P. Svenningsson,et al. The noradrenergic subtype of Parkinson disease: from animal models to clinical practice , 2023, Nature Reviews Neurology.
[4] C. Vitale,et al. Sleep and wakefulness disturbances in Parkinson's disease: A meta-analysis on prevalence and clinical aspects of REM sleep behavior disorder, excessive daytime sleepiness and insomnia. , 2023, Sleep medicine reviews.
[5] K. Jellinger. The pathobiological basis of depression in Parkinson disease: challenges and outlooks , 2022, Journal of Neural Transmission.
[6] R. Postuma. Neuroprotective Trials in REM Sleep Behavior Disorder , 2022, Neurology.
[7] Houeto Jean-Luc. [Parkinson's disease]. , 2022, La Revue du praticien.
[8] S. Saffari,et al. Association Between Parkinson’s Disease and Coronary Artery Disease: A Systematic Review and Meta-Analysis , 2022, Journal of Parkinson's disease.
[9] I. Kouri,et al. Restless Legs Syndrome and Periodic Limb Movements of Sleep: From Neurophysiology to Clinical Practice. , 2022, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.
[10] T. Sakurai,et al. Rapid eye movement sleep is initiated by basolateral amygdala dopamine signaling in mice , 2022, Science.
[11] Shoji Nakamura. Integrated pathophysiology of schizophrenia, major depression, and bipolar disorder as monoamine axon disorder. , 2022, Frontiers in bioscience.
[12] Chieh-Sen Chuang,et al. Association between β2-Adrenoreceptor Medications and Risk of Parkinson’s Disease: A Meta-Analysis , 2021, Medicina.
[13] Alejandro Osorio-Forero,et al. Noradrenergic circuit control of non-REM sleep substates , 2021, Current Biology.
[14] R. Barker,et al. Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson’s disease , 2021, Nature Genetics.
[15] D. Brooks,et al. Progressive loss of raphe nuclei serotonin transporter in early Parkinson's disease: A longitudinal 123I-FP-CIT SPECT study. , 2020, Parkinsonism & related disorders.
[16] P. De Deurwaerdère,et al. The Noradrenergic System in Parkinson’s Disease , 2020, Frontiers in Pharmacology.
[17] J. Growdon,et al. Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson's Disease in the Harvard Biomarkers Study. , 2020, Journal of Parkinson's disease.
[18] Bilal A. Bari,et al. Locus coeruleus-norepinephrine: basic functions and insights into Parkinson’s disease , 2019, Neural regeneration research.
[19] D. Shin,et al. Association of statin use with Parkinson's disease: Dose–response relationship , 2019, Movement disorders : official journal of the Movement Disorder Society.
[20] J. Chen,et al. Nicotine improved the olfactory impairment in MPTP-induced mouse model of Parkinson's disease. , 2019, Neurotoxicology.
[21] M. Nalls,et al. The Parkinson’s phenome—traits associated with Parkinson’s disease in a broadly phenotyped cohort , 2019, npj Parkinson's Disease.
[22] T. Friede,et al. Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa) , 2018, Movement disorders : official journal of the Movement Disorder Society.
[23] C. Glorioso,et al. Nicotine promotes neuron survival and partially protects from Parkinson’s disease by suppressing SIRT6 , 2018, Acta Neuropathologica Communications.
[24] N. Gronich,et al. β2‐adrenoceptor agonists and antagonists and risk of Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.
[25] F. Turkheimer,et al. Serotonergic dysregulation is linked to sleep problems in Parkinson's disease , 2018, NeuroImage: Clinical.
[26] P. Remy,et al. High‐dose transdermal nicotine in Parkinson's disease patients: a randomized, open‐label, blinded‐endpoint evaluation phase 2 study , 2018, European journal of neurology.
[27] R. Marconi,et al. Head trauma and Parkinson’s disease: results from an Italian case-control study , 2017, Neurological Sciences.
[28] I. Roy,et al. Nicotine slows down oligomerisation of α-synuclein and ameliorates cytotoxicity in a yeast model of Parkinson's disease. , 2017, Biochimica et biophysica acta. Molecular basis of disease.
[29] Nir Giladi,et al. Statin adherence and the risk of Parkinson's disease: A population-based cohort study , 2017, PloS one.
[30] Alison I. Bernstein,et al. Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease , 2017, Proceedings of the National Academy of Sciences.
[31] A. Ascherio,et al. The epidemiology of Parkinson's disease: risk factors and prevention , 2016, The Lancet Neurology.
[32] Zhiguo Sheng,et al. Statin use and risk of Parkinson’s disease: A meta-analysis , 2016, Behavioural Brain Research.
[33] Robert L. Sielken,et al. Association between Parkinson’s Disease and Cigarette Smoking, Rural Living, Well-Water Consumption, Farming and Pesticide Use: Systematic Review and Meta-Analysis , 2016, PloS one.
[34] M. Weisskopf,et al. Head injury at early ages is associated with risk of Parkinson's disease. , 2016, Parkinsonism & related disorders.
[35] Cheng-Ta Li,et al. Risk of developing Parkinson's disease among patients with asthma: a nationwide longitudinal study , 2015, Allergy.
[36] K. Chaudhuri,et al. The range and nature of non-motor symptoms in drug-naive Parkinson’s disease patients: a state-of-the-art systematic review , 2015, npj Parkinson's Disease.
[37] A. Nordström,et al. Depression and subsequent risk of Parkinson disease , 2015, Neurology.
[38] C. Tu,et al. The association between chronic obstructive pulmonary disease and Parkinson's disease: a nationwide population-based retrospective cohort study. , 2014, QJM : monthly journal of the Association of Physicians.
[39] Xiang Gao,et al. Restless legs syndrome: an early clinical feature of Parkinson disease in men. , 2014, Sleep.
[40] L. Marsh,et al. Depression and Parkinson’s Disease: Current Knowledge , 2013, Current Neurology and Neuroscience Reports.
[41] M. Harris,et al. Head injuries and Parkinson's disease in a case-control study , 2013, Occupational and Environmental Medicine.
[42] M. Etminan,et al. Head injury and risk of Parkinson disease: A systematic review and meta‐analysis , 2013, Movement disorders : official journal of the Movement Disorder Society.
[43] Honglei Chen,et al. Head injury and Parkinson's disease: A population‐based study , 2012, Movement disorders : official journal of the Movement Disorder Society.
[44] A. Lees,et al. Meta-Analysis of Early Nonmotor Features and Risk Factors for Parkinson Disease , 2012, Annals of neurology.
[45] K. Hirata,et al. [Depression and anxiety in Parkinson's disease]. , 2012, Brain and nerve = Shinkei kenkyu no shinpo.
[46] C. Tanner,et al. Rotenone, Paraquat, and Parkinson’s Disease , 2011, Environmental health perspectives.
[47] Manuel B. Graeber,et al. PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease , 2010, Science Translational Medicine.
[48] Charles R. Yang,et al. Current perspectives of the roles of the central norepinephrine system in anxiety and depression , 2010, Depression and anxiety.
[49] J. Olsen,et al. Risk of Parkinson’s disease after hospital contact for head injury: population based case-control study , 2008, BMJ : British Medical Journal.
[50] C. Nemeroff,et al. The role of dopamine in the pathophysiology of depression. , 2007, Archives of general psychiatry.
[51] J. Jankovic,et al. Exploring the relationship between Parkinson disease and restless legs syndrome. , 2002, Archives of neurology.
[52] W. Poewe,et al. Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration , 1999, Movement disorders : official journal of the Movement Disorder Society.
[53] M. Nefzger,et al. A retrospective study of smoking in Parkinson's disease. , 1968, American journal of epidemiology.
[54] D. Bansal,et al. Statin use and risk of Parkinson’s disease: a meta-analysis of observational studies , 2012, Journal of Neurology.
[55] S. Spangenberg,et al. A nationwide population study of severe head injury and Parkinson's disease. , 2009, Parkinsonism & related disorders.
[56] P. Vieregge,et al. Transdermal nicotine in PD : A randomized , double-blind , placebo-controlled study , 2002 .